Journal List > J Korean Ophthalmol Soc > v.52(1) > 1008978

Lee and Jin: Clinical Results of Riboflavin and Ultraviolet-A-induced Corneal Crosslinking for Progressive Keratoconus in Korean Patients

Abstract

Purpose

To report the clinical results of 10 progressive keratoconic eyes in Korean patients treated by corneal cross-linking and compare the progression of keratoconus in the fellow eyes.

Methods

This present retrospective case series was comprised of 10 progressive keratoconic eyes (10 patients) that had corneal cross-linking. Patients were examined before corneal cross-linking as well as 1, 3, 6, 9, and 12 months postoperatively. The main outcome measures were best corrected visual acuity, maximum keratometry, mean keratometry, corneal thickness, corneal astigmatism and endothelial cell count.

Results

The best corrected visual acuity (logMAR) improved from 0.60 ± 0.39 to 0.52 ± 0.38 at 12 months postoperatively. The maximum keratometry decreased from 62.39 ± 8.82 D preoperatively to 60.21 ± 9.21 D at 12 months postoperatively and the mean keratometry decreased from 51.59 ± 5.86 D to 50.04 ± 6.21 D at 12 months. In addition, the corneal thickness (at the thinnest area) decreased from 433.60 ± 44.31 μ m to 403.40 ± 38.95 μ m at 12 months. There was no statistically significant difference between the preoperative and 12 months postoperative endothelial cell count (p = 0.731).

Conclusions

This present 1-year follow-up study of Korean keratoconus patients showed corneal cross-linking appeared to be effective in the stabilizing progression of keratoconus and improving best corrective visual acuity and keratometry.

References

1. Wollensak G. Crosslinking treatment of progressive keratoconus: new hope. Curr Opin Ophthalmol. 2006; 17:356–60.
crossref
2. Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg. 2008; 34:796–801.
crossref
3. Kim HS, Lee TH, Lee KH. Intracorneal ring segment implantation for the management of keratoconus: short-term safety and efficacy. J Korean Ophthalmol Soc. 2009; 50:1505–9.
crossref
4. Wollensak G, Spoerl E, Seiler T. Stress-strain measurements of human and porcrine cornea after riboflavin/ultraviolet-A-induced crosslinking. J Cataract Refract Surg. 2003; 29:1780–5.
5. Wollensak G, Wilsch M, Spoerl E, Seiler T. Collagen fiber diameter in the rabbit cornea after collagen crosslinking by riboflavin/ UVA. Cornea. 2004; 23:503–7.
6. Spoerl E, Wollensak G, Seiler T. Increased resistance of cross-linked cornea against enzymatic digestion. Curr Eye Res. 2004; 29:35–40.
crossref
7. Mencucci R, Marini M, Paladini I, et al. Effects of riboflavin/UVA corneal crosslinking on keratocytes and collagen fibres in human cornea. Clin Experiment Ophthalmol. 2010; 38:49–56.
crossref
8. Wollensak G, Spoerl E, Seiler T. Riboflavin/Ultraviolet-A-induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003; 135:620–7.
crossref
9. Wittig-Silva C, Whiting M, Lamoureux E, et al. A randomized controlled trial of corneal collagen crosslinking in progressive keratoconus: preliminary results. J Refract Surg. 2008; 24:s720–5.
crossref
10. Grewal DS, Brar GS, Jain R, et al. Corneal collagen crosslinking using riboflavin and ultraviolet-A light for keratoconus: one-year analysis using Scheimpflug imaging. J Cataract Refract Surg. 2009; 35:425–32.
11. Vinciguerra P, Albe E, Trazza S, et al. Refractive, topographic, tomographic, and abberometric analysis of keratoconic eyes undergoing corneal crosslinking. Ophthalmology. 2009; 116:369–78.
12. Koller T, Iseli HP, Hafezi F, et al. Scheimpflug imaging of corneas after collagen crosslinking. Cornea. 2009; 28:510–5.
crossref
13. Vinciguerra P, Albe E, Trazza S, et al. Intraoperative and postoperative effects of corneal collagen crosslinking on progressive keratoconus. Arch Ophthalmol. 2009; 127:1258–65.
crossref
14. Caporossi A, Mazzotta C, Baiocchi S, Caporossi T. Long-term results of riboflavin ulatraviolet A corneal collagen crosslinking for keratoconus in Italy: the Seina eye cross study. Am J Ophthalmol. 2010; 149:585–93.
15. Choi HJ, Kim MK, Lee JL. Diagnostic criteria for keratoconus using Orbscan II slit scanning topography/pachymetry system. J Korean Ophthalmol Soc. 2004; 45:928–35.
16. Tu KL, Aslanides M. Orbscan II anterior elevation changes following conrneal collagen crosslinking treatment for keratoconus. J Refract Surg. 2009; 25:715–22.
17. Spoerl E, Mrochen M, Sliney D, et al. Safety of UVA-riboflavin crosslinking of the cornea. Cornea. 2007; 26:385–9.
crossref
18. Bakke EF, Stojanovic A, Chen X, Drolsum L. Penetration of riboflavin and postoperative pain in corneal collagen crosslinking. Excimer laser superficial versus mechanical full-thickness epithelial removal. J Cataract Refract Surg. 2009; 35:1363–6.
19. Kymionis GD, Kounis GA, Portaliou DM, et al. Intraoperative pachymetric measurements during corneal collagen crosslinking with riboflavin and ultraviolet a irradiation. Ophthalmology. 2009; 116:2336–9.
crossref
20. Koller T, Mrochen M, Seiler T. Complication and failure rates after corneal crosslinking. J Cataract Refract Surg. 2009; 35:1358–62.
crossref
21. Kymionis GD, Kontadakis GA, Kounis GA, et al. Simultaneous topography-guided PRK followed by corneal collagen crosslinking for keratoconus. J Refract Surg. 2009; 25:s807–11.
crossref
22. Chan CC, Sharma M, Wachler BS. Effect of inferior-segment intacs with and without C3-R on keratoconus. J Cataract Refract Surg. 2007; 33:75–80.
crossref

Figure 1.
(A) Mean change in maximum keratometry between baseline and 3, 6, 9, and 12 months for treatment and control groups. (B) Mean change in mean keratometry between baseline and 3, 6, 9, and 12 months for treatment and control groups. (C) Mean change in corneal astigmatism between baseline and 3, 6, 9, and 12 months for treatment and control groups. (D) Mean change in BCVA between baseline and 3, 6, 9, and 12 months for treatment and control groups. (E) Mean change in apex corneal thickness between baseline and 3, 6, 9, and 12 months for treatment and control groups (At each time point, the bar represents the mean change from baseline and the p value is calculated using independent samples t-test between control and treatment group).
jkos-52-23f1.tif
Table 1.
Pre-and postoperative data after corneal cross-linking at different time points
Measurement (mean ± SD) Pre-CCL Postoperative follow-up (months)
1 3 6 12
BCVA* (logMAR) 0.60 ± 0.39 0.60 ± 0.40 0.54 ± 0.34 0.50 ± 0.30 0.52 ± 0.38
Maximum keratometry (D) 62.39 ± 8.82 63.39 ± 10.04 61.85 ± 9.98 61.34 ± 9.40 60.21 ± 9.21
Mean keratometry (D) 51.59 ± 5.86 51.81 ± 6.34 50.93 ± 6.45 50.68 ± 6.53 50.40 ± 6.21
Thinnest corneal thickness (μ m) 433.60 ± 44.31 403.00 ± 40.63 393.70 ± 27.05 396.80 ± 31.68 403.40 ± 38.95
Apex corneal thickness (μ m) 444.90 ± 53.06 413.50 ± 53.07 408.50 ± 56.53 408.70 ± 51.17 422.70 ± 42.85
Corneal astigmatism (D) 6.92 ± 1.53 6.80 ± 2.63 7.09 ± 2.92 6.65 ± 2.27 6.22 ± 2.11

* Best corrected visual acuity

Corneal cross-linking.

Table 2.
Comparison of parameters measured preoperatively and at 12 months in the cross-linked (treated) eyes and control fellow eyes
Measurement (mean) Treatment eyes
Non-treated eyes (control)
Pre 12 M p-value Pre 12 M p-value
BCVA (logMAR)* 0.60 0.52 0.145 0.18 0.19 0.555
Maximum keratometry (D) 62.39 60.21 0.087 53.14 54.05 0.189
Mean Keratometry (D) 51.59 50.40 0.048 46.96 47.61 0.041
Thinnest Corneal thickness (μ m) 433.60 403.40 0.002 455.60 449.10 0.116
Apex Corneal thickness (μ m) 444.90 422.70 0.126 483.70 481.60 0.431
Corneal astigmatism (D) 6.92 6.22 0.089 2.77 3.53 0.002

* Best corrected visual acuity

Paired sample t-test between pre-treatment and 12-month follow-up.

TOOLS
Similar articles